Global Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class - Opportunity Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 3.6% - ResearchAndMarkets.com

DUBLIN--()--The "Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class - Global Opportunity Analysis and Industry Forecast, 2017-2023" report has been added to ResearchAndMarkets.com's offering.

The global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023.

Aneurysmal subarachnoid hemorrhage (aSAH) is a condition wherein a brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, leading to paralysis or coma, and even death. The National Institutes of Health (NIH) has stated that aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden, with high fatality and permanent disability rates.

The major factors driving the global aneurysmal subarachnoid hemorrhage market are rise in prevalence of diseases such as stroke and hypertension, and surge in geriatric population. In addition, lifestyle modifications, such as increased alcohol consumption and smoking, further increase the risk for aSAH, which in turn stimulates the market growth. However, the associated side effects of drugs and medication taken during the treatment of aneurysmal subarachnoid hemorrhage restrain the market growth. Furthermore, the growth in awareness about the treatment of the aSAH is expected to provide numerous opportunities for the market growth in future.

The global aneurysmal subarachnoid hemorrhage market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Companies Mentioned:

  • Arbor Pharmaceuticals Inc.
  • Edge Therapeutics, Inc.
  • Johnson & Johnson
  • Mylan N.V.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Pharmaxis, Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Drug Class

Chapter 5: Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Region

Chapter 6: Company Profile

For more information about this report visit https://www.researchandmarkets.com/research/tbngh5/global_aneurysmal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs